Impact on microbiology laboratory turn-around-times following process improvements and total laboratory automation.

Carolyn Gonzalez-Ortiz, M(ASCP)CM,[1] Alanna Emrick, MLS(ASCP)CM SMCM, [1] Ying P. Tabak, PhD,[2] Latha Vankeepuram, MS,[2] Stephen Kurtz, MS,[2] David Sellers, BS,[2] Megan Wimmer, MBA,[2] Caitlin Asjes, MS,[2] Suhaireirene Suady Barake, MD,[3] Jacob Nichols, MD,[3] Fatma Levent, MD,[3#]

Affiliations:

[1] University Medical Center, Lubbock, TX

[2] Becton, Dickinson and Company, Franklin Lakes, NJ

[3]Texas Tech University Health Sciences Center, Lubbock, TX

#To whom correspondence should be addressed:

Fatma Levent, MD, Clinical Associate Professor
Pediatric Infectious Diseases / Department of Pediatrics
Texas Tech Health Sciences Center
Lubbock, TX
Phone: 806-392-4976
Fax: 806-743-2314
Email: fatma.levent@ttuhsc.edu

Source of support: This work was supported in part by Becton, Dickinson and Company

Running title: Improved lab efficiency with automation

Abbreviations: TLA, total laboratory automation; SOP, standard operating procedure; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight mass spectrometry; TAT, turn-around time; ID, identification; ASM, American Society of Microbiology; CLSI, Clinical Laboratory Standards Institute; MT, medical technologist

ABSTRACT

Introduction: The impact of workflow changes and total laboratory automation (TLA) on microbiology culture processing time was evaluated in an academic-affiliated regional hospital.

Materials and Methods: A retrospective analysis of microbiological data in a research database was performed to compare turnaround time (TAT) for organism identification (ID) before and after implementation of TLA (2013 versus 2016, respectively). TAT was compared using x2 test for categorical variables and log-transformed t-test for continuous variables.

Results: A total of 9,351 pre-defined common and clinically important positive mono-bacterial culture results were included in the analysis. Shorter TAT (hours) in 2016 compared to 2013 ($p<0.0001$) for positive result pathogen ID were observed in specimen types including blood (40.7 vs. 47.1), urine (30 vs 44), wound (39.6 vs. 60.2), respiratory (47.7 vs. 67), and all specimen types, combined (43.3 vs. 56.8). Although shorter TAT were not observed from all specimen categories for negative result pathogen ID, TAT for all specimen types, combined, was shorter ($p\leq0.001$) in 2016 compared to 2013 (94 vs. 101).

Conclusions: Total laboratory automation and workflow changes—including process standardization—facilitate shorter organism ID TAT across specimen sources.

Key Words: Total laboratory automation, Microbiology, Laboratory testing, Laboratory workflow, Turnaround time

INTRODUCTION

Total laboratory automation (TLA) of the clinical microbiology laboratory typically consists of automation for plating, incubation, reading, and processing of specimens. Studies have demonstrated the clinical value of automating microbiological workflow including enhanced microbial growth, better colony isolation, reduced requirement for bacterial subculture, and reduced time to results.(1-5) Previous work suggests that TLA can facilitate rapid reporting of microbiology culture testing and thereby inform the management of infectious disease and lead to enhanced patient care.(5-7)

This need for laboratory automation comes from an increased demand for clinical microbiology laboratory services, despite growing staffing challenges.(8-10) Successful automation of a laboratory requires a thorough assessment and appropriate refinement of all laboratory workflow practices that might impact system efficiency.(11, 12) This includes consideration of extending service delivery to a twenty-four hour day, seven days per week (24/7) schedule.(2, 12, 13) Such changes facilitate the maximum benefit from laboratory automation.

Previous work demonstrated that TLA can also improve laboratory workflow, efficiency, and reproducibility(5, 8, 14, 15) while reducing errors.(3, 7) Staffing reductions of approximately 30% have been reported after automation despite a 27% increase in average laboratory-workload per day.(2) Thus, TLA addresses the challenges associated with a high volume work load and allows managers to reallocate human resources to value-added activities.

In 2014, the University Medical Center (UMC), Lubbock, TX prioritized improvements to quality and efficiency in the microbiology laboratory—including moving to TLA. After an assessment of available TLA solutions, UMC leadership supported investment in the BD Kiestra™ TLA system (Kiestra; Becton, Dickinson and Company, BD Life Sciences—BD Integrated Diagnostic Systems, Sparks, MD, USA), which automates and standardizes sample setup, incubation, and reading. UMC became the second laboratory in the United States to implement Kiestra TLA and the first to both operate 24/7 as well as have all microbial sample types on the system. Preparation for the transition to automation included changes in laboratory policy and processes. The hypothesis here was that a combination of TLA and foundational workflow improvements (made in anticipation of the new technology associated with TLA), would result in a shorter post-TLA turnaround time (TAT). Although previous studies have evaluated the use of TLA for single specimen sources,(4-6, 16-21) the goal here was to evaluate TAT across a wide range of specimen sources.

MATERIALS AND METHODS

Study Design

We compared microbiological result TAT before and after implementation of TLA and process improvements, including implementation of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF) (Bruker Daltonik, Germany).(22) The laboratory process improvement preparation started in 2014 and the TLA system went live in May 2015. The entire calendar years of 2013 and 2016 were used as pre- and post-periods, respectively, to evaluate TAT before and after laboratory technology and process changes. The year 2016 was selected as steady state to account for an implementation preparation period and a process-stabilization period after TLA implementation in 2015. This study was approved by the Quality Improvement Review Board at Texas Tech University Health Sciences Center. This work was condicted in a manner consistent with the ideals set forth by the World Medical Association Declaration of Helsinki regarding ehical conduct of research involving human subjects.

Process improvement in preparation for TLA

Review of SOPs

Process improvements and total laboratory automation at the study site went through a stepwise and intricate process (see Figure 1). The initial steps were taken to ensure that process improvement evaluations were generated/updated that align with the College of American Pathologists guidelines for an accredited laboratory (https://www.cap.org/laboratory-improvement/accreditation/laboratory-accreditation-program). In April 2014, all SOPs were modified as needed according to procedural need; however they remained aligned with American Society of Microbiology (ASM) (23) and Clinical Laboratory and Standards Institute (CLSI) guidelines,(24) as well as, community practice standards, in an effort that involved networking with physician groups.

Staff education

All medical technologists (MTs) were actively engaged in professional education, assigned specific topics, and responsible for retraining the department on their respective roles and monitoring compliance with the updated workflow practices. All MTs were educated and tested on best practice as described in the Clinical Microbiology Procedures Handbook.(9)

Streamlined culture order code options and standardization of agar plate setup

The UMC microbiology laboratory standardized culture set-ups and streamlined the number of order codes from 49 to 31. The standardization project resolved variability by narrowing plate setups to a single option and setting clear expectations for reading plates. Completing these projects simultaneously in November 2014 allowed for all MTs to be trained on all sources in preparation for the automation line, where cultures would be prepared for reading during setup. Digital imaging offered on the TLA system enabled plate images to be taken at ideal incubation times. This allowed reading of the plates to be optimally timed by reviewing the images rather than the plates themselves.(13, 17, 25)

Improved communication between laboratory and physician groups

Communication between laboratory management and physician/clinician groups during the TLA implementation period was approached here in a manner similar to that reported previously.(26-28) A diagnostic management team was created prior to commencing the transition to TLA. The team consisted of laboratory management and different physician/clinician groups and included several goals. First, the team was created to ensure more consistent, open communication between the laboratory and clinicians. Initial meetings included communication on process changes for ordering, testing, and downstream activities including reporting, charting, and consultation between physician/clinician and laboratory management. Team meetings covered adjustments by the clinician to receive laboratory results in a reduced time frame in order to convert the time savings to a potential benefit for patients through evidence-based practices. Feedback from physician/clinician groups was received by the laboratory regarding TLA-related issues, such as patient charting based on the previous collection day. Related to charting, discussion items included any changes in test selection and result interpretation based on TLA implementation. Laboratory updates were provided to physician/clinician groups at team meetings throughout the TLA implementation process. Post implementation meetings revealed the physician/clinician perspectives on progress based on initial goal setting for processes including reporting and charting, and offered feedback to the laboratory for continued improvement.

Pre and Post-TLA sample processing

During the 2013 study period, specimens arrived for processing throughout the day and specimen login to the laboratory information system was considered the initial time point for TAT (this also applies to 2016). For the conventional plating technique, urine specimens were streaked manually using calibrated loops onto Blood and MacConkey agar plates and placed into incubators. Specimen plating occurred in batches and incubation initially occurred overnight (minimum of 18 hours) and plate reading was performed on four source benches including Blood/Cerebral Spinal Fluid (CSF), Wound/Tissue/Body Fluid, Urine, and Stool/Respiratory, each combining all plates into one batch during the morning. However, upon review, many plates were being read early at 16 hours per work day from 6 am to10 pm (i.e. many plates that were prepared very early during the day shift [~6 am] were read at the end of the day shift [~10 pm]). Spot testing, which included oxidase catalase, pyrrolidonyl arylamidase, desoxycholate, indole, numerous latex agglutination tests, urease, and coagulase tests for Staphylococcus aureus, were conducted when required for identification. The BD Phoenix™ system (Becton, Dickinson and Company, BD Integrated Diagnostic Systems, Sparks, MD), A disk, P disk, RapID™ Systems (Thermo Fisher, Waltham, MA), or API® ID Strips (bioMérieux, Marcy-l'Étoile, France) were utilized for identification following all spot testing.

Kiestra TLA was implemented in May 2015 (Figure 1). Using TLA, specimens were inoculated, upon reception (no batching), onto the appropriate agar plate type by the BD Kiestra InoculA+ system (InoculA), and plates were automatically transported via BD Kiestra ProceedA to ReadA Compact (incubation). Digital images of the plates were

automatically acquired at 18, 42, and 66 hours depending on the sample type, (i.e. 18 hours for day one, 42 hours for day two, 66 hours for day three). Positive plates were sent to the ErgonomicA, where a technologist performed MALDI-TOF MS for identification. Spot testing was reduced to only indole and desoxycholate for MALDI confirmation requirements, and coagulase and latex agglutination for a more rapid ID of S. aureus and β-hemolytic streptococci, respectively. Bruker MALDI-TOF MS was implemented in February 2016 for gram-negative IDs; gram-positive IDs were added in October 2016 and anaerobe and yeast IDs were added in April 2017. MALDI-TOF MS replaced identification by conventional methods—times to result for positive specimens, preliminary negatives, and antimicrobial test reporting were recorded as described above. All other spot testing and ID methods were fully replaced with MALDI-TOF MS. A similar workflow was utilized to identify cultures as negative. Plates identified as no growth or no pathogens at 18 hours were further incubated for an additional 24 hours for a total of 42 hours before a second image analysis was performed. Times to result for positive specimens and preliminary negatives were as described above.

Specimen Source and Organism Identification

Specimens were classified by source as blood, urine, wound, respiratory, intra-abdominal, and other. The top ten common and clinically relevant bacteria seen in the laboratory were included: Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes (Group A), Streptococcus agalactiae (Group B), Pseudomonas aeruginosa, Proteus mirabilis, Enterococcus faecalis, and Enterococcus faecium. Results from 19.3% in 2013 and 20.2% in 2016 of the total results at each, respective year, from the microbiology laboratory are included in this study. The analysis was restricted to positive specimen results for mono-bacterial isolates of interest and negative culture results.(6, 17, 23, 29)

Definition of definitive results TAT

We assessed definitive positive organism identification (ID) TAT as time from laboratory log-in of specimen to the earliest definitive positive result reporting time. Likewise, the TAT for negative results were from laboratory log-in to the earliest definitive negative result report.

Data Source

De-identified digital microbiological data were captured in a research database (BD Insights) created by Becton, Dickinson and Company (Franklin Lakes, NJ).(18, 19, 21) The dataset for the current study included: specimen collection time, source, laboratory log-in time, and culture results reporting time.

Statistical analysis

We analyzed organism ID reporting time over a 24-hour spectrum. Definitive positive organism ID and negative results TAT for pre- versus post-periods were compared. The x2 test for categorical variables and log-transformed t-test for

continuous variables was utilized for comparisons. A two-tailed p-value of <0.05 was considered statistically significant. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).

RESULTS

Overall 4,510 positive results were reported (Table 1). The mean TAT for all specimen types was significantly shorter after TLA and process change implementation (2106) compared to pre-TLA (2013) (all $p<0.05$).The overall TAT mean (standard deviation) was 43.3 (20.8) hours versus 56.8 (24.3) hours for years 2016 and 2013, respectively. Figures 2a-d depict the comparison of cumulative distribution of TAT for positive IDs for the four most common specimen sources (blood, urine, wound, and respiratory; all $P<0.05$). For blood specimens, the ID TAT was 53% (2016) versus 17% (2013) by 48 hours from laboratory login time (Figure 2a). For specimens derived from urine, wound, and respiratory, a higher percentage of results were returned within 24 hours in 2016 compared to 2013. At least 40% of the urine, wound, and respiratory had TAT <36 hours in 2016, whereas in 2013, 40% of wound and respiratory had TAT >36 hours, and 40% of urine TAT exceeded 24 hours. For urine specimens, the ID TAT was 51% (2016) versus 14% (2013) by 36 hours from laboratory login time (Figure 2b). For respiratory specimens, the ID TAT was 59% (2016) versus 21% (2013) by 48 hours from laboratory login time (Figure 2c). For wound specimens, the ID TAT was 77% (2016) versus 39% (2013) by 48 hours from laboratory login time (Figure 2d).

Overall 58,640 negative results were reported (Table 2). All sources except for respiratory and “other” showed shortened TAT (all $p<0.05$). Figures 3a-d depict the comparison of cumulative distribution of negative result TAT for the four most common sources (blood, urine, wound, and respiratory; all $p<0.05$). For blood specimens, the TAT was 95% (2016) versus 73% (2013) by 128 hours from laboratory login time (Figure 3a). TAT for specimens derived from urine and wound showed the greatest reduction in 2016 compared to 2013. For urine specimens, the TAT was 83% (2016) versus 10% (2013) by 36 hours from laboratory login time (Figure 3b). For wound specimens, the ID TAT was 71% (2016) versus 36% (2013) by 96 hours from laboratory login time (Figure 3c). For respiratory specimens, the negative results TAT was 79% (2016) versus 86% (2013) by 96 hours from laboratory login time (Figure 3d). Negative results TAT was less variable across the time frame categories for blood and respiratory between 2013 and 2016; however, the 80th percentile of TAT results for blood were returned within 126 to 128 hours in 2016 while those in 2013 were delayed to between 128 to 240 hours.

DISCUSSION

The results here suggest that TLA, in conjunction with process changes that facilitate TLA, led to improvement in TAT for microbial ID. Although the observed shorter TAT was likely a joint effect of intricate laboratory process improvement and implementation of the TLA, these results are in agreement with previous studies that show a positive correlation between laboratory automation and faster TAT. (17-21, 27) In general, the overall laboratory process improvement interventions and TLA implementation (2016) led to shorter TAT when compared to 2013 for positive results. For the highest volume specimen, urine cultures, pathogen ID TAT improved by an average of 6.4 hours from 2013 to 2016. Since TLA processes and images the plates under consistent incubation conditions, facilitating more robust growth,(17) a 16 to 30 hour growth period was no longer necessary; this likely facilitated earlier ID. Blood cultures showed significant improvement in TAT to pathogen positive ID by 19 hours, potentially enabling providers to update their course of treatment by almost an entire day for patients with bacteremia. In addition to urine and blood cultures, wound, respiratory, intra-abdominal, and "other" cultures showed improvements of 20.6, 19.3, 12.2, and 22.5 hours, respectively(Table 1, Figure 2). The use of a combination of the ReadA Compact smart incubators, which reduce the incubation time needed, and MALDI-TOF for ID of gram-negative organisms, which reduces the time to definitive ID; both could contribute to improvement in TAT.

The implementation of laboratory process improvements incorporating TLA largely led to reductions in TAT for negative culture results. For urines, the average time to report a negative result in 2016 improved by 14 hours compared to 2013. Prior to TLA implementation, all negative urine cultures were read manually, which necessitated pulling plates from the incubator racks by hand. TLA standardizes incubation duration, so cultures are available to read at the appropriate time as opposed to times that might be dictated by staff availability or other daily workflow considerations. Digital imaging allows negative urines to be read on-screen, reducing the manual labor of removing each plate from the incubator and occurred at the 18-hour mark with TLA. These approaches are consistent with current CLSI and ASM guidelines.(23, 24) Due, most likely to TLA capabilities, including digital imaging and improved incubation times, read time for the majority of urine cultures was reduced to one day, with the exception of suprapubic, straight catheter, cystoscopy, and nephrostomy sources. The results of negative wound cultures were obtained an entire day sooner. Process changes prior to TLA were made that included the removal of thioglycolate broths from the wound cultures and a reduction in plate incubation times. Improvements in TAT for respiratory and "other" were not observed for negative results. The microbiology laboratory reported that respiratory and "other" specimens grew many isolates that were more difficult to identify at first pass. Analyses involved with this study were focused on single isolate cultures. Respiratory and "other" specimen types often grew isolates that were mixed, overgrown, and/or mucoid. Subcultures were often necessary, delaying ID TAT; for the mucoid specimens, repeated IDs were sometimes necessary, causing delays.

The significant time savings reported here were likely due to several factors. The overall laboratory process improvement interventions, including SOP update, staff education, and hospital-wide collaborations, are likely integral parts of the improvement in the shortened ID TAT. In addition, the TLA system aided in reducing TAT through a number of key technical components. Because ESwabsTM (Copan Diagnostics Inc., Murrieta, CA, USA) and BD Vacutainer™ (Becton, Dickinson and Company, Franklin Lakes, NJ) system-collected urines could be fully automated, there was more than a 75% reduction in manual plate inoculation. The system includes a plate-streaking module, the InoqulA, which has been shown to improve colony isolation through automated plate streaking.(1, 3, 4) BD Kiestra TLA also features a component called the ReadA Compact, a "smart" incubator, which does not require interruptions during the incubation process in order to improve growth conditions.(6, 14) The physical connection between the InoqulA module, ReadA Compact, and the ProceedA (a track that automates movement of specimens between modules) minimizes the time plates spend in the open air at room temperature; plates are instead transported by the ProceedA to the ReadA Compact within minutes. Moreno-Camacho et al. demonstrated that the ReadA Compact uses enhanced organism growth cycles and improved the rate of viable organisms available for further identification and accurate susceptibility testing.(14) Standardization of specimen preparation and detection methods has been shown to limit the potential for variability and to reduce manual reconciliation and interpretation by individual technologists.(3)

Previously, cultures received a non-standardized 24 hours of incubation. Incubation times varied from 16 to 30 hours of first incubation prior to TLA and process changes. Ongoing process review and refinement to maintain adherence to current guidelines also precipitated further removal of redundant or obsolete steps from manual processes (such as certain broth incubations) for specific specimen types. Interestingly, we found that laboratory process improvement and TLA implementation led to a more even distribution of clinical results during a 24-hour time spectrum (Figure S1). However, in line with previous discussion regarding work distribution following TLA implementation,(30) we view a more even distribution of workflow across a 24 hour work period as an indicator of improved workflow efficiency that reflects reductions in unnecessary or excessive work and/or idle/waiting time. Automation of negative result identification further allows laboratory personnel to focus on other important aspects of clinical work by, for example, allowing more time to read positive plates that require technical skill. This idea is supported by previous work, for example, Greub et al estimated that 50–70% of the time spent by full-time technicians may be saved by automation of pre-analytical sample preparation and plate inoculation alone.(31)

This study has limitations. Since this is a retrospective observational study of a microbiology laboratory TAT improvement in a real world setting, each intervention was not pre-designed to last long enough time to allow for assessment of independent impact. The standardization and workflow improvement activities were integral parts of TLA implementation, where each intervention often overlapped with other interventions, the attributable impact of each component attributable to the shortened TAT could not be measured independently. This resulted in an inability to clearly delineate the proportion of TAT improvement attributable to process improvement versus TLA. Likewise, MALDI-

TOF was not fully integrated (to include yeast identification along with Gram negative and Gram positive bacteria) until 2017, which admittedly affected our capability of fully assessing the impact of TLA at the time of study. A goal for future studies will be to further investigate this continued quality improvement. Another limitation is that we did not directly assess whether improved (shorter) TAT was associated with improved patient outcomes, which is beyond the scope of this study. Nevertheless, performance values following TLA using Kiestra have previously been demonstrated.(16, 25, 32) Furthermore, previous work has been able to provide more direct evidence for a benefit of specific automation components after the implementation TLA. For example, Theparee et al (Ref 27) were able to isolate the impact of TLA (median ID TAT decrease of ~ 2hours compared to pre-TLA) and of MALDI-TOF (median ID TAT decrease of ~3 hours compared to TLA alone).(19) Mutters et al (Ref 5), combined TLA and MALDI-TOF together versus conventional testing, however, they completely implemented the MALDI-TOF library at one time—as opposed to the stepwise implementation of Gram negative, Gram positive, and yeast organisms over the course of one to two years as occurred in this study site. In that study TLA, combined with MALDI-TOF led to an anti-biotic switch in 12% of cases (in addition to those cases in which a switch was based on Gram staining) in addition to shortening the first 24 hour incubation time. Ultimately, however, randomized, controlled trials will be required to better "…evaluate the actual benefits of an automated system in terms of morbidity, mortality, and health care costs."(5)

Conclusions

In contrast to previous studies involving TLA impact on clinical processes involving a single specimen type,(6, 17, 18) this study describes the significant impact of TLA and related process changes on decreased TAT in microbial ID across a broad range of specimen types. A combination of TLA and associated workflow improvements contribute to shorter definitive organism ID TAT across all specimen sources and shorter TAT for negative results for most specimen sources. Overall, there was an average of approximately 13.5 hours improvement in TAT to organism ID across all subsets of cultures for which data were analyzed. Additionally, the overall TAT to negative result for all cultures, even with the regression of some cultures due to process change, improved an average of approximately 7 hours. Future studies could further investigate the relationship of operationalizing TLA technology in conjunction with workflow optimization and potentially identify positive impacts on patient care by informing and thereby enabling physicians to make antibiotic therapy choices sooner.

ACKNOWLEDGEMENTS

The authors thank Devin S. Gary, PhD (Becton, Dickinson and Company, BD Life Sciences – Diagnostic Systems) and Andrea Gwosdow, PhD (Consultant for Becton, Dickinson and Company, BD Life Sciences – Diagnostic Systems), for insight, discussion, and review during the preparation of this manuscript. The individual acknowledged here has no additional funding or additional compensation to disclose.

DISCLOSURES

This study was approved by the Quality Improvement Review Board of the study site. The researchers at Texas Tech University Health Sciences Center, University Medical Center, Lubbock, TX, and Becton, Dickinson and Co. Franklin Lakes, NJ conducted the analysis as their normal working responsibilities. YPT, LV, SK, DS, MW, CA are current or former employees of Becton, Dickinson, and Company, the manufacturer of the BD Kiestra TLA system implemented by the study site. AE, CGO, SS, JN, and FL do not have any other disclosures. All authors provided final approval of the manuscript and agree to be accountable for the accuracy and integrity of this work..

1. Croxatto A, Dijkstra K, Prod'hom G, Greub G. Comparison of Inoculation with the InoculA and WASP Automated Systems with Manual Inoculation. J Clin Microbiol. 2015;53(7):2298-307.

2. Croxatto A, Prod'hom G, Faverjon F, Rochais Y, Greub G. Laboratory automation in clinical bacteriology: what system to choose? Clin Microbiol Infect. 2016;22(3):217-35.

3. Froment P, Marchandin H, Vande Perre P, Lamy B. Automated versus manual sample inoculations in routine clinical microbiology: a performance evaluation of the fully automated InoculA instrument. J Clin Microbiol. 2014;52(3):796-802.

4. Iversen J, Stendal G, Gerdes CM, Meyer CH, Andersen CO, Frimodt-Moller N. Comparative Evaluation of Inoculation of Urine Samples with the Copan WASP and BD Kiestra InoculA Instruments. J Clin Microbiol. 2016;54(2):328-32.

5. Mutters NT, Hodiamont CJ, de Jong MD, Overmeijer HP, van den Boogaard M, Visser CE. Performance of Kiestra total laboratory automation combined with MS in clinical microbiology practice. Ann Lab Med. 2014;34(2):111-7.

6. Dauwalder O, Landrieve L, Laurent F, de Montclos M, Vandenesch F, Lina G. Does bacteriology laboratory automation reduce time to results and increase quality management? Clin Microbiol Infect. 2016;22(3):236-43.

7. Matthews S, Deutekom J. The future of diagnostic bacteriology. Clin Microbiol Infect. 2011;17(5):651-4.

8. Carden R, Allsbrook K, Thomas R. An examination of the supply and demand for clinical laboratory professionals in the United States. Transfusion. 2009;49(11 Pt 2):2520-3.

9. Garcia E, Ali AM, Soles RM, Lewis DG. The American Society for Clinical Pathology's 2014 vacancy survey of medical laboratories in the United States. Am J Clin Pathol. 2015;144(3):432-43.

10. Ward-Cook K. Medical laboratory workforce trends and projections: what is past is prologue. Clinical leadership & management review : the journal of CLMA. 2002;16(6):364-9.

11. Hawker CD. Nonanalytic Laboratory Automation: A Quarter Century of Progress. Clinical chemistry. 2017;63(6):1074-82.

12. Murray PR. Laboratory automation: efficiency and turnaround times. Micro Austr. 2014;35(1).

13. Humphrey G. MC, Gough H., Awadel-Kariem F.M. Experience with KIESTRA's Total Lab Automation solution to meet the challenge of universal MRSA screening for Lister Hospital, a large UK district general hospital. Clinical Microbiology and Infection. 2011;17(Supp 4).

14. Moreno-Camacho JL, Calva-Espinosa DY, Leal-Leyva YY, Elizalde-Olivas DC, Campos-Romero A, Alcántar-Fernández J. Transformation From a Conventional Clinical Microbiology Laboratory to Full Automation. Laboratory Medicine. 2017;49(1):e1-e8.

15. Thomson RB, Jr., McElvania E. Total Laboratory Automation: What Is Gained, What Is Lost, and Who Can Afford It? Clin Lab Med. 2019;39(3):371-89.

16. Klein S, Nurjadi D, Horner S, Heeg K, Zimmermann S, Burckhardt I. Significant increase in cultivation of Gardnerella vaginalis, Alloscardovia omnicolens, Actinotignum schaalii, and Actinomyces spp. in urine samples with total laboratory automation. Eur J Clin Microbiol Infect Dis. 2018;37(7):1305-11.

17. Graham M, Tilson L, Streitberg R, Hamblin J, Korman TM. Improved standardization and potential for shortened time to results with BD Kiestra total laboratory automation of early urine cultures: A prospective comparison with manual processing. Diagn Microbiol Infect Dis. 2016;86(1):1-4.

18. Yarbrough ML, Lainhart W, McMullen AR, Anderson NW, Burnham CD. Impact of total laboratory automation on workflow and specimen processing time for culture of urine specimens. Eur J Clin Microbiol Infect Dis. 2018;37(12):2405-11.

19. Theparee T, Das S, Thomson RB, Jr. Total Laboratory Automation and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Improve Turnaround Times in the Clinical Microbiology Laboratory: a Retrospective Analysis. J Clin Microbiol. 2018;56(1).

20. Burckhardt I, Horner S, Burckhardt F, Zimmermann S. Detection of MRSA in nasal swabs-marked reduction of time to report for negative reports by substituting classical manual workflow with total lab automation. Eur J Clin Microbiol Infect Dis. 2018;37(9):1745-51.

21. Tabak YP, Vankeepuram L, Ye G, Jeffers K, Gupta V, Murray PR. Blood Culture Turnaround Time in U.S. Acute Care Hospitals and Implications for Laboratory Process Optimization. J Clin Microbiol. 2018;56(12).

22. Zilberberg MD, Tabak YP, Sievert DM, Derby KG, Johannes RS, Sun X, et al. Using electronic health information to risk-stratify rates of Clostridium difficile infection in US hospitals. Infection control and hospital epidemiology. 2011;32(7):649-55.

23. Carroll KC, Pfaller MA, Landry ML, McAdam AJ, Patel R, Richter SS, et al. Manual of Clinical Microbiology, Twelfth Edition: American Society of Microbiology; 2019.

24. Patel JM, Cockerill FR, Eliopoulos GM, Jenkins SG, Lewis JS, Limbago B, et al. CLSI. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Third Informational Supplement. CLSI document M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute. 2014.

25. Heather CS, Maley M. Automated direct screening for resistance of Gram-negative blood cultures using the BD Kiestra WorkCell. Eur J Clin Microbiol Infect Dis. 2018;37(1):117-25.

26. Buehler SS, Madison B, Snyder SR, Derzon JH, Cornish NE, Saubolle MA, et al. Effectiveness of Practices To Increase Timeliness of Providing Targeted Therapy for Inpatients with Bloodstream Infections: a Laboratory Medicine Best Practices Systematic Review and Meta-analysis. Clin Microbiol Rev. 2016;29(1):59-103.

27. De Socio GV, Di Donato F, Paggi R, Gabrielli C, Belati A, Rizza G, et al. Laboratory automation reduces time to report of positive blood cultures and improves management of patients with bloodstream infection. Eur J Clin Microbiol Infect Dis. 2018;37(12):2313-22.

28. Maurer FP, Christner M, Hentschke M, Rohde H. Advances in Rapid Identification and Susceptibility Testing of Bacteria in the Clinical Microbiology Laboratory: Implications for Patient Care and Antimicrobial Stewardship Programs. Infectious disease reports. 2017;9(1):6839.

29. Garcia L. Clinical Microbiology Procedures Handbook, 3rd Edition2010.

30. Burckhardt I. Laboratory Automation in Clinical Microbiology. Bioengineering (Basel, Switzerland). 2018;5(4).

31. Greub G, Prod'hom G. Automation in clinical bacteriology: what system to choose? Clin Microbiol Infect. 2011;17(5):655-60.

32. Croxatto A, Marcelpoil R, Orny C, Morel D, Prod'hom G, Greub G. Towards automated detection, semi-quantification and identification of microbial growth in clinical bacteriology: A proof of concept. Biomed J. 2017;40(6):317-28.

Figure Legend

Figure 1: Microbiology Laboratory Quality Improvement Process Illustration

Figure 2: Definitive positive bacterial pathogen ID turnaround time following login by most common source: a) Blood, b) Urine, c) Respiratory, and d) Wound.

Figure 3: Definitive negative culture results turnaround time following login by most common source: a) Blood, b) Urine, c) Respiratory, and d) Wound

[a]The extended time reported for blood cultures reflects an initial growth/detection phase prior to plating.

Supplemental Figure 1: Organism ID reporting time distribution during a 24-hour spectrum.

Tables
Table 1

Table 1. Descriptive statistics for definitive positive bacterial pathogen ID turnaround time (hours)

Specimen	Year	n	Mean (SD)	Median (IQR)	p-value[a]
Blood	2013	759	70.6 (28.9)	62.8 (52.0, 74.5)	<.0001
	2016	882	51.2 (19.2)	46.6 (38.0, 59.1)	
Urine	2013	2,282	47.1 (14.9)	43.6 (38.0, 48.9)	<.0001
	2016	2,306	40.7 (18.8)	35.5 (27.7, 47.9)	
Wound	2013	1,160	60.2 (25.6)	58.6 (43.1, 69.2)	<.0001
	2016	869	39.6 (21.3)	32.8 (25.6, 47.0)	
Respiratory	2013	461	67.0 (23.5)	65.3 (49.8, 74.7)	<.0001
	2016	369	47.7 (24.9)	41.9 (28.1, 57.7)	
Intra-abdominal	2013	23	69.9 (28.8)	64.3 (53.1, 84.7)	0.0368
	2016	34	57.8 (32.1)	49.9 (25.7, 78.2)	
Other[b]	2013	56	75.1 (57.4)	64.5 (46.4, 89.8)	0.0013
	2016	50	52.6 (30.5)	46.1 (29.3, 69.7)	
Overall	2013	4,741	56.8 (24.3)	48.4 (41.1, 66.4)	<.0001
	2016	4,510	43.3 (20.8)	38.0 (28.7, 51.7)	

Abbreviations: SD, standard deviation; IQR: inter-quartile range (1st, 3rd quartile)

[a]Log-transformed t-test for continuous variables, utilized for comparisons of mean turnaround time.
[b]"Other" includes specimens from duodenal aspirate, ear, eye, quantitative tissue, quantitative bronchospcopy, environmental samples (surgical hardware, transfusion reactions), stool, Cystic Fibrosis cultures, dialysates, catheter tips, cerebral spinal fluid, genital, and throat

Table 2

Table 2. Descriptive statistics for negative result turn-around-time (in hours)

Specimen	Year	n	Mean (SD)	Median (IQR)	p-value[a]
Blood	2013	16,393	131 (54)	126 (122, 128)	<.0001
	2016	17,905	125 (6)	125 (123, 127)	
Urine	2013	8,115	44 (10)	45 (40, 47)	<.0001
	2016	8,880	30 (14)	26 (22, 32)	
Wound	2013	1,100	108 (40)	114 (74, 120)	<.0001
	2016	957	82 (43)	66 (50, 113)	
Respiratory	2013	1,204	62 (30)	50 (45, 64)	<.0001[b]
	2016	1,460	71 (36)	54 (47, 80)	
Intra-abdominal	2013	154	129 (26)	117 (113, 156)	<.0001
	2016	280	115 (40)	122 (103, 132)	
Other[c]	2013	613	121 (15)	118 (114, 123)	<.0001[b]
	2016	674	170 (27)	175 (164, 184)	
Overall	2013	27,579	101 (58)	121 (48, 127)	<.0001
	2016	30,156	94 (47)	123 (38, 126)	

Abbreviations: SD, standard deviation; IQR: inter-quartile range (1st, 3rd quartile)

[a]Log-transformed t-test for continuous variables, utilized for comparisons of mean turnaround time.
[b] For respiratory and "other" sources, the negative turn-around-time was shorter in 2013.
[c]"Other" includes specimens from duodenal aspirate, ear, eye, quantitative tissue, quantitative bronchospcopy, environmental samples (surgical hardware, transfusion reactions), stool, Cystic Fibrosis cultures, dialysates, catheter tips, cerebral spinal fluid, genital, and throat

Figures
Figure 1

Figure 1.



Figure 2


Figure 2.
Blood
Urine
Wound
Respiratory
Cumulative frequency
100%
80%
60%
40%
20%
0%
≤24
>24 to ≤36
>36 to ≤48
>48 to ≤72
>72 to ≤96
>96
Positive results turnaround time (hours)
2013
2016

Figure 3


Figure 3.
Blood
Cumulative frequency
100%
80%
60%
40%
20%
0%
≤120
>120 - ≤122
>122 - ≤124
>124 - ≤126
>126 - ≤128
>128 - ≤240
>240
Negative results turnaround time (hours)
2013
2016
Urine
Cumulative frequency
≤24
>24 to ≤36
>36 to ≤48
>48 to ≤72
>72 to ≤96
>96 to ≤120
>120
Negative results turnaround time (hours)
2013
2016
Wound
Cumulative frequency
≤24
>24 to ≤36
>36 to ≤48
>48 to ≤72
>72 to ≤96
>96 to ≤120
>120
Negative results turnaround time (hours)
2013
2016
Respiratory
Cumulative frequency
≤24
>24 to ≤36
>36 to ≤48
>48 to ≤72
>72 to ≤96
>96 to ≤120
>120
Negative results turnaround time (hours)
2013
2016

Supplemental Figure 1